Analyst Price Targets — KZIA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 1, 2026 10:38 am | Kambiz Yazdi | BTIG | $34.00 | $14.08 | TheFly | Kazia Therapeutics initiated with a Buy at BTIG |
| June 11, 2026 11:40 am | — | Lake Street | $32.00 | $11.50 | TheFly | Kazia Therapeutics initiated with a Buy at Lake Street |
| April 15, 2026 9:00 am | — | Laidlaw | $25.00 | $9.46 | TheFly | Kazia Therapeutics initiated with a Buy at Laidlaw |
| December 12, 2025 11:09 am | — | H.C. Wainwright | $18.00 | $13.09 | TheFly | Kazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright |
| October 2, 2025 1:01 pm | — | Maxim Group | $20.00 | $6.84 | TheFly | Kazia Therapeutics price target raised to $20 from $15 at Maxim |
Latest News for KZIA
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience across…
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced plans to expand its ongoing Phase 1b clinical trial…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KZIA.
U.S. House Trading
No House trades found for KZIA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.